{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:52:10Z","timestamp":1781304730934,"version":"3.54.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1321,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1111\/j.1365-2133.2011.10693.x","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T00:09:41Z","timestamp":1318810181000},"page":"616-623","source":"Crossref","is-referenced-by-count":79,"title":["Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome"],"prefix":"10.1093","volume":"166","author":[{"given":"J.","family":"Cort\u00e9s-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Torres-Salido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Castro-Marrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vilardell-Tarres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ordi-Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,1,19]]},"reference":[{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/08916930600886851","article-title":"Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies","volume":"39","author":"Lee","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0190-9622(81)80261-7","article-title":"Distinctive cutaneous subsets in the spectrum of lupus erythematosus","volume":"4","author":"Gilliam","year":"1981","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0560.2001.280101.x","article-title":"The cutaneous pathology of lupus erythematosus: a review","volume":"28","author":"Crowson","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/archderm.1975.01630230050009","article-title":"Discoid lupus erythematosus as part of a larger disease spectrum. Correlation of clinical features with laboratory findings in lupus erythematosus","volume":"111","author":"Prystowsky","year":"1975","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jaad.2010.06.018","article-title":"Cutaneous lupus erythematosus: update of therapeutic options. Part I","volume":"65","author":"Kuhn","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.berh.2005.05.003","article-title":"Management of \u2018refractory\u2019 skin disease in patients with lupus erythematosus","volume":"19","author":"Callen","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.jaad.2010.06.017","article-title":"Cutaneous lupus erythematosus: update of therapeutic options. Part II","volume":"65","author":"Kuhn","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: dermatological indications, mechanisms of action and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archderm.139.1.50","article-title":"Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus","volume":"139","author":"Housman","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.2000.00953.x","article-title":"Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus","volume":"39","author":"Kyriakis","year":"2000","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2133.1983.tb04600.x","article-title":"Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus","volume":"108","author":"Knop","year":"1983","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1590\/S0104-42301998000400007","article-title":"Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus","volume":"44","author":"Sato","year":"1998","journal-title":"Rev Assoc Med Bras"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB13|cit13","first-page":"1429","article-title":"Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy","volume":"27","author":"Ordi-Ros","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/rheumatology\/36.3.353","article-title":"Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients","volume":"36","author":"Stevens","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1191\/0961203305lu2124oa","article-title":"Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients","volume":"14","author":"Coelho","year":"2005","journal-title":"Lupus"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.amjmed.2004.04.030","article-title":"Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens","volume":"118","author":"Cuadrado","year":"2005","journal-title":"Am J Med"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archderm.135.9.1079","article-title":"American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus","volume":"135","author":"Duong","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/mcne.1999.0770","article-title":"P75-mediated NF-Kappa B activation enhances the survival response of developing sensory neurons to nerve growth factor","volume":"14","author":"Hamanouse","year":"1999","journal-title":"Mol Cell Neurosci"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB19|cit19","first-page":"53","volume-title":"Cutaneous Lupus Erythematosus","author":"Kuhn","year":"2004"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revisited criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","article-title":"The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus","volume":"125","author":"Albrecht","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB22|cit22","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/1529-0131(199812)41:12<2273::AID-ART26>3.0.CO;2-6","article-title":"Thalidomide induces amenorrhea in patients with lupus disease","volume":"41","author":"Ordi","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2133.2009.09472.x","article-title":"Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients","volume":"162","author":"Vera-Recabarren","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.7326\/0003-4819-97-5-664","article-title":"Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus","volume":"97","author":"Sontheimer","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/1523-1747.ep12616582","article-title":"Clinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus","volume":"99","author":"David-Bajar","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-4362.2000.00866.x","article-title":"Clinical and immunological parameters during thalidomide treatment of lupus erythematosus","volume":"39","author":"Walchner","year":"2000","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archderm.1994.01690010070009","article-title":"Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients","volume":"130","author":"Ochonisky","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/08916930500285790","article-title":"Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus","volume":"38","author":"Briani","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mus.880090907","article-title":"Thalidomide neuropathy: an electrophysiologic study","volume":"9","author":"Lagueny","year":"1986","journal-title":"Muscle Nerve"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/archderm.1984.01650470072016","article-title":"Thalidomide induced peripheral neuropathy","volume":"120","author":"Aronson","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB32|cit32","first-page":"313","article-title":"Actualite du Thalidomide","volume":"117","author":"Revuz","year":"1990","journal-title":"Ann Dermatol Venerol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of mucocutaneous lesions of the Beh\u00e7et\u2019s syndrome: a randomized, double blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB35|cit35","first-page":"171","article-title":"Thalidomide and thrombosis","volume":"127","author":"Flageul","year":"2000","journal-title":"Ann Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0248-8663(02)00648-3","article-title":"Accidents thrombotiques favoris\u00e9s par le thalidomide: deux observations","volume":"23","author":"Gachon","year":"2002","journal-title":"Rev Med Interne"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1468-3083.2006.01819.x","article-title":"Acute myocardial infarction in a patient with cutaneous lupus erythematosus treated with thalidomide","volume":"21","author":"Llambrich","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2011.10693.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1191\/0961203302lu180ed","article-title":"Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus","volume":"11","author":"Piette","year":"2002","journal-title":"Lupus"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2011.10693.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2011.10693.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T08:53:57Z","timestamp":1676364837000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/166\/3\/616\/6613769"}},"subtitle":["Thalidomide in refractory CLE"],"short-title":[],"issued":{"date-parts":[[2012,1,19]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10693.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718010193.793476596","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1,19]]}}}